Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy

Late-stage diagnosis of lung cancer occurs ~95% of the time due to late manifestation of its symptoms, necessitating rigorous treatment following diagnosis. Existing treatment methods are limited by lack of specificity, systemic toxicity, temporary remission, and radio-resistance in lung cancer cell...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Menon, Jyothi U., Kuriakose, Aneetta, Iyer, Roshni, Hernandez, Elizabeth, Gandee, Leah, Zhang, Shanrong, Takahashi, Masaya, Zhang, Zhang, Saha, Debabrata, Nguyen, Kytai T.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5643549/
https://ncbi.nlm.nih.gov/pubmed/29038584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-13320-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak